Tag:

Omontys

Latest Headlines

Latest Headlines

Affymax, once a promising biotech, is dissolving

Affymax, which 18 months ago appeared poised for big things, is dissolving the company and will pay shareholders pennies for the shares that traded at $27 a share before patient deaths led it to pull its Omontys anemia drug from the market.

Affymax, once a promising biotech, is dissolving

Affymax, which 18 months ago appeared poised for big things, is dissolving the company and will pay shareholders pennies for the shares that traded at $27 a share before patient deaths led it to pulled its Omontys anemia drug from the market.

FDA saw early reports of severe Omontys reactions: WSJ

The anemia drug Omontys triggered serious allergic reactions long before February's recall, The Wall Street Journal reports.

Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy

Without the fuel of Omontys sales, the small drugmaker is basically running on fumes.

Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy

In the wake of last month's Omontyx recall, Affymax is jettisoning three-fourths of its staff and considering bankruptcy. Without the fuel of Omontys sales, the small drugmaker is basically running on fumes. And it has to spend money to investigate the hypersensitivity reactions--and patient deaths--that triggered the recall. So, out comes the cost-cutting ax.

UPDATED: Affymax, Takeda pull Omontys after 3 deaths

Severe hypersensitivity reactions in Omontys patients prompted Affymax and Takeda Pharmaceutical to recall all lots of the anemia drug, designed for use in dialysis patients.

Takeda, Affymax nail supply deal for Omontys anemia drug

Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.

Affymax banks $50M milestone on ESA drug approval

Affymax has banked a $50 million check from its partner Takeda after they won FDA approval for an anemia treatment that will now compete with Amgen for market share.

Affymax approval breaks Amgen's long anemia monopoly

Now that FDA has approved a new, independent amenia drug competitor, will Amgen's versions plummet?

Affymax breaks Amgen's anemia drug monopoly with ESA approval

Amgen has finally lost control of the U.S. market for anemia drugs needed to treat dialysis patients.